Diana M. Mooij-Sprij
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
The IGF pathway is activated in insulinomas but downregulated in metastatic disease.
Journal: Endocrine-related cancer
Published: June 28, 2018
Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells.
Journal: Neuroendocrinology
Published: December 23, 2014
Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy.
Journal: European journal of endocrinology
Published: October 30, 2013
Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
Journal: The Journal of clinical endocrinology and metabolism
Published: October 02, 2013
Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors.
Journal: Endocrine connections
Published: September 18, 2013
Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.
Journal: Endocrine-related cancer
Published: March 20, 2013
Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly.
Journal: The Journal of clinical endocrinology and metabolism
Published: November 03, 2012
Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion.
Journal: The Journal of clinical endocrinology and metabolism
Published: November 18, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026